Growth Metrics

Disc Medicine (IRON) Debt Ratio (2020 - 2022)

Disc Medicine (IRON) reported Debt Ratio of 0.03 for Q2 2022, down 43.82% year-over-year from 0.05 in Q2 2021, and down 23.19% on a QoQ basis from 0.03 in Q1 2022.

Disc Medicine (IRON) has 3 years of Debt Ratio data on file, last reported at 0.03 in Q2 2022.

  • Quarterly Debt Ratio fell 43.82% year-over-year to 0.03 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was 0.03 (down 43.82% YoY) and the FY2021 annual result came in at 0.07, down 93.8% from the prior year.
  • Debt Ratio eased to 0.03 in Q2 2022 per IRON's latest filing, from 0.03 in the prior quarter.
  • Across five years, Debt Ratio topped out at 1.2 in Q4 2020 and bottomed at 0.03 in Q2 2022.
  • The 3-year median for Debt Ratio is 0.05 (2021), against an average of 0.21.
  • The widest annual swing landed in 2021, when Debt Ratio sank 93.8%; it then slumped 30.58% in 2022.
  • Tracing IRON's Debt Ratio over 3 years: stood at 1.2 in 2020, then slumped by 93.8% to 0.07 in 2021, then tumbled by 65.35% to 0.03 in 2022.
  • Per Business Quant, the three latest IRON Debt Ratio figures stand at 0.03 (Q2 2022), 0.03 (Q1 2022), and 0.07 (Q4 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 1.41
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Disc Medicine 2.76 Bn 2.03 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 0.03
Mar 31, 2022 0.03
Dec 31, 2021 0.07
Sep 30, 2021 0.04
Jun 30, 2021 0.05
Mar 31, 2021 0.05
Dec 31, 2020 1.20